ciPTEC Human Renal Cell Lines — Nephrotoxicity & Drug Transporter Assays | DMPK | SeamlessBio

ciPTEC Human Renal Cell Lines — Nephrotoxicity & Drug Transporter Assays | DMPK

ciPTEC (conditionally immortalised proximal tubule epithelial cells) are the gold standard human in vitro model for renal drug transporter studies and nephrotoxicity assessment. Developed by the Department of Pharmacology and Toxicology at Radboud University Medical Center and protected under patent PCT/EP2010/066792, ciPTEC cells express the full complement of clinically relevant renal transporters endogenously — making them the most physiologically representative human renal cell model available for early-stage DMPK and safety studies.

Over 90 peer-reviewed publications validate ciPTEC performance across nephrotoxicity, DDI, and transporter mechanistic studies. SeamlessBio supplies ciPTEC cell lines and assay services via Cell4Pharma.

  Key validation milestone: ciPTEC-OAT1 validated in collaboration with AstraZeneca across 62 compounds — 75% sensitivity, 100% specificity for nephrotoxicity prediction. This is the most rigorously validated human renal in vitro model published to date.

Why the Kidney is the Critical Organ for Drug Safety

The proximal tubule is the primary site of drug-induced kidney injury (DIKI / nephrotoxicity). Proximal tubule epithelial cells (PTECs) are uniquely vulnerable because they express high concentrations of uptake transporters (OAT1, OAT3, OCT2) on the basolateral membrane — actively concentrating drugs from the blood into the tubular cells — while efflux transporters (P-gp, MRP4, BCRP, MATE1/2) on the apical membrane drive secretion into the tubular lumen. Drugs that inhibit efflux while still being taken up accumulate to toxic concentrations inside PTECs.

Drug-induced nephrotoxicity is frequently missed in preclinical animal models and only detected during clinical trials — accounting for up to 25% of acute kidney injury in hospitalised patients and numerous late-stage drug failures. ciPTEC provides the human-specific transporter expression profile necessary to predict these failures early.

ciPTEC Cell Line Portfolio

Cell Line	Transporter Expression	Primary Application
ciPTEC Parental	OCT2 P-gp (ABCB1) MRP2 MRP4 BCRP Megalin/Cubilin	General nephrotoxicity screening, cell viability assays, efflux transporter activity, OCT2-mediated uptake studies. Base model — stable for 20+ passages.
ciPTEC-OAT1	OAT1 (SLC22A6) OCT2 P-gp MRP2 MRP4 BCRP MATE1/2	Most comprehensive renal in vitro model available. FDA/EMA DDI-enabling studies for OAT1 substrates and inhibitors. Antiviral nephrotoxicity (adefovir, cidofovir, tenofovir). Validated: 75% sensitivity, 100% specificity across 62 compounds (AstraZeneca collaboration).
ciPTEC-OAT3	OAT3 (SLC22A8) OCT2 P-gp MRP2 BCRP	Basolateral organic anion uptake studies. Complete renal transport characterisation alongside ciPTEC-OAT1. NSAIDs, diuretics, beta-lactam antibiotics. OAT3-mediated drug-drug interactions.

Culture medium tip: ciPTEC cells require Human Serum AB for supplementation. SeamlessBio supplies Human Serum AB Male Off-the-Clot — the recommended grade for ciPTEC culture protocols.

Renal Transporter Map — What ciPTEC Expresses

Transporter	Gene	Location	Direction	Key Substrates	In ciPTEC
OAT1	SLC22A6	Basolateral	Uptake (blood → cell)	Antivirals (adefovir, tenofovir), NSAIDs, beta-lactams, diuretics	ciPTEC-OAT1 ✅
OAT3	SLC22A8	Basolateral	Uptake	Furosemide, statins, NSAIDs, estrone sulfate	ciPTEC-OAT3 ✅
OCT2	SLC22A2	Basolateral	Uptake	Metformin, cisplatin, creatinine, cimetidine	All variants ✅
P-gp (MDR1)	ABCB1	Apical	Efflux (cell → lumen)	Digoxin, vincristine, paclitaxel	All variants ✅
MRP2	ABCC2	Apical	Efflux	Glucuronide conjugates, methotrexate	All variants ✅
MRP4	ABCC4	Apical	Efflux	Nucleoside analogues, prostaglandins, diuretics	Parental + OAT1 ✅
BCRP	ABCG2	Apical	Efflux	Sulfate conjugates, methotrexate, statins	All variants ✅
MATE1/2	SLC47A1/2	Apical	Efflux	Metformin, creatinine, OCT2 substrates	ciPTEC-OAT1 ✅
Megalin/Cubilin	LRP2 / CUBN	Apical	Endocytosis	Albumin, amino-glycosides, vitamin D binding protein	Parental ✅

Available Assay Services (via Cell4Pharma)

Assay	Cell Line	Readout	Regulatory Use
Nephrotoxicity screening	ciPTEC Parental / OAT1	Cell viability (MTT, LDH, fluorescence), mitochondrial function, membrane integrity — multi-parametric	Early drug discovery safety screening — identifies renal toxic liabilities before in vivo studies
OAT1 transport & inhibition	ciPTEC-OAT1	Fluorescein uptake inhibition, IC50 determination	FDA 2020 / EMA 2013 DDI — OAT1 (SLC22A6) required for renally eliminated compounds
OAT3 transport & inhibition	ciPTEC-OAT3	Estrone sulfate / fluorescein uptake inhibition, IC50	FDA 2020 / EMA 2013 DDI — OAT3 (SLC22A8) required alongside OAT1
OCT2 transport & inhibition	ciPTEC Parental / OAT1	ASP+ fluorescent substrate uptake, IC50	FDA 2020 DDI — OCT2 required for cationic compounds and renal secretion assessment
MATE1/2 inhibition	ciPTEC-OAT1	ASP+ efflux inhibition, IC50	FDA 2020 DDI — MATE1 and MATE2-K required alongside OCT2
Vectorial transport (basolateral → apical)	ciPTEC-OAT1 (polarised)	Full transepithelial transport measurement across polarised monolayer	Mechanistic renal secretion modelling — OAT1 + efflux transporter interaction
High-content nephrotoxicity	ciPTEC-OAT1	5-parameter fluorescence panel: nucleus, mitochondria, lysosomes, membrane, cytoskeleton	High-throughput lead optimisation screening — identify mechanism of toxicity

Regulatory Context

Guideline	Required Renal Transporters	ciPTEC Coverage
FDA 2020 DDI Guidance	OCT2, OAT1, OAT3, MATE1, MATE2-K	✅ Full coverage — ciPTEC-OAT1 covers all 5
EMA 2013 DDI Guideline	OCT2, OAT1, OAT3	✅ Full coverage
ICH M12 (2023)	OCT2, OAT1, OAT3, MATE1/2 — risk-based	✅ Full coverage via ciPTEC-OAT1
Nephrotoxicity prediction	No defined guideline — but FDA flagged DIKI as clinical trial risk signal	✅ ciPTEC-OAT1 validated for DIKI prediction — 75% sensitivity, 100% specificity

ciPTEC vs Other Renal In Vitro Models

Model	Transporter Expression	Human Origin	Stability	Validation
ciPTEC (Cell4Pharma)	✅ Full panel — OAT1, OAT3, OCT2, P-gp, MRP2/4, BCRP, MATE1/2	✅ Human	✅ 20+ passages stable	✅ 90+ publications, AstraZeneca validation
HEK293 transfected (single transporter)	Single transporter only — no endogenous renal panel	✅ Human (embryonic kidney)	✅ Stable	Limited to single transporter
MDCK-MDR1 / MDCK-BCRP	Single efflux transporter — canine background	❌ Canine	✅ Stable	P-gp/BCRP substrates only
Primary human PTECs	✅ Full panel — native expression	✅ Human	❌ Limited passages — lot variability	Limited — donor-dependent variability
Animal PTECs (rat, mouse)	Rodent transporter orthologues — species differences	❌ Animal	Limited	Poor human translation

Key Publications

ciPTEC is backed by more than 90 peer-reviewed publications across nephrotoxicity, DDI, and transporter characterisation. Selected key references:

Study	Key Finding
Jansen et al., AAPS J. 2016	ciPTEC-OAT1 and -OAT3 characterised for antiviral nephrotoxicity prediction — direct OAT involvement in adefovir, cidofovir, tenofovir toxicity demonstrated
Wilmer et al., Arch Toxicol. 2018	High-content 5-parameter screening assay in ciPTEC-OAT1 — identifies nephrotoxic compounds with mechanism of injury in early drug discovery
AstraZeneca validation (published)	62-compound blind validation — 75% sensitivity, 100% specificity for nephrotoxicity prediction using ciPTEC-OAT1

Also Available — ABC Transporter Vesicle Kits

For hepatic ABC transporter assessment (BSEP, MRP1–5, MRP8, Pgp, BCRP) SeamlessBio also supplies ready-to-use vesicle kits from Cell4Pharma for in-house DMPK screening. → ABC Transporter Vesicle Kits

Request a quote or study design Order cell lines or technical consultation

DMPK panel pricing, assay service scopes, regulatory support: info@seamlessbio.de | +49 851 37932226